A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma

I3Y-MC-JPCJ -

The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Pancreatic Cancer
What the trial is testing?
Abemaciclib, Capecitabine, Galunisertib, Gemcitabine, Samotolisib
Could I receive a Placebo?
No
Enrollment Goal
106
Trial Dates
Jan 12, 2017 - Nov 9, 2018
How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment and how many cycles of treatment you receive.
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.